Cardiac Biotech Solutions Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2018	FY 2017
Period Ending	Dec '18 Dec 31, 2018	Mar '18 Mar 31, 2018	Mar '17 Mar 31, 2017
Revenue	0.05	0.04	0.03
Revenue Growth (YoY)	-	11.11%	-
Cost of Revenue	0.02	0.01	0.02
Gross Profit	0.03	0.02	0.02
Selling, General & Admin	0.46	0.49	0.37
Other Operating Expenses	0.66	0.66	0.02
Operating Expenses	0.78	1.15	0.39
Operating Income	-0.75	-1.13	-0.37
Other Non Operating Income (Expenses)	0.11	-	-0.02
Pretax Income	-0.64	-1.13	-0.39
Net Income	-0.64	-1.13	-0.39
Net Income to Common	-0.64	-1.13	-0.39
Shares Outstanding (Basic)	59	58	57
Shares Outstanding (Diluted)	59	58	57
Shares Change (YoY)	-	1.52%	-
EPS (Basic)	-0.01	-0.02	-0.01
EPS (Diluted)	-0.01	-0.02	-0.01
Free Cash Flow	-	-0.77	-0.06
Free Cash Flow Per Share	-	-0.01	-0.00
Gross Margin	54.34%	64.15%	49.32%
Operating Margin	-1486.00%	-3090.31%	-1122.17%
Profit Margin	-1271.68%	-3090.31%	-1171.49%
Free Cash Flow Margin	-	-2109.05%	-191.28%
EBITDA	-	-1.13	-0.37
D&A For EBITDA	-	0	0
EBIT	-0.75	-1.13	-0.37

Source: S&P Capital IQ. Standard template. Financial Sources.